Background

This is a pilot proof-of-concept study to evaluate the utility of a custom 15-gene circulating tumor DNA (ctDNA) panel as a potential companion molecular next-generation sequencing (NGS) assay for identifying somatic single nucleotide variants and indels in non-small-cell lung cancer (NSCLC) patients. The custom panel covers the hotspot mutations in EGFR, KRAS, NRAS, BRAF, PIK3CA, ERBB2, MET, KIT, PDGFRA, ALK, ROS1, RET, NTRK1, NTRK2 and NTRK3 genes which serve as biomarkers for guiding treatment decisions in NSCLC patients.

Method

The custom 15-gene ctDNA NGS panel was designed using ArcherDX Assay Designer. A total of 20 ng or 50 ng input ctDNA was used to construct the libraries. The analytical performance was evaluated using reference standards at different allellic frequencies (0.1%, 1%, 5% and parental). The clinical performance was evaluated using plasma samples collected from 10 treatment naïve advanced stage III or IV NSCLC patients who were tested for tissue EGFR mutations. The bioinformatics analysis was performed using the proprietary Archer Analysis Software.

Results

For the analytical validation, we achieved 100% sensitivity and specificity for the detection of known mutations in the reference standards. The limit of detection was 1% allelic frequency. Clinical validation showed that the clinical sensitivity and specificity of the assay for detecting EGFR mutation were 83.3% and 100% respectively. In addition, the NGS panel also detected other mutations of uncertain significance in 6 out of 10 patients.

Conclusion

This preliminary analysis showed that the custom 15-gene ctDNA NGS panel demonstrated good analytical and clinical performances for the EGFR mutation. Further studies incorporating the validation of other candidate gene mutations are warranted.

1. International Agency for Research on Cancer. (2020). Malaysia source document: Cancer fact sheets. World Health Organization. https://gco.iarc.fr/today/data/factsheets/populations/458-malaysia-fact-sheets.pdf
2. Ministry of Health Malaysia. (2019). Malaysia National Cancer Registry Report 2012–2016. National Cancer Registry, Department of Intelligence, Ministry of Health Malaysia. https://www.moh.gov.my/moh/resources/Penerbitan/Laporan/Umum/2012-2016%20(MNCRR)/MNCR_2012-2016_FINAL_(PUBLISHED_2019).pdf
3. Passiglia, F., Galvano, A., Gristina, V., Barraco, N., Castiglia, M., Perez, A., ... & Bazan, V. (2021). Is there any place for PD-1/CTLA-4 inhibitors combination in the first-line treatment of advanced NSCLC?—A trial-level meta-analysis in PD-L1 selected subgroups. Translational Lung Cancer Research, 10(7), 3106–3119. https://doi.org/10.21037/tlcr-21-42
4. Shi, Y., Lei, Y., Liu, L., Zhang, S., Wang, W., Zhao, J., ... & Fang, J. (2021). Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer. Cancer Medicine, 10(7), 2216–2231. https://doi.org/10.1002/cam4.3720
5. Alexander, M., Kim, S. Y., & Cheng, H. (2020). Update 2020: Management of non-small cell lung cancer. Lung, 198(6), 897–907. https://doi.org/10.1007/s00408-020-00407-y
6. Chen, R., Manochakian, R., James, L., Azzouqa, A. G., Shi, H. S., Zhang, Y., ... & Zhao, Y. (2020). Emerging therapeutic agents for advanced non-small cell lung cancer. Journal of Hematology & Oncology, 13(1), Article 58. https://doi.org/10.1186/s13045-020-00881-7
7. Lamberti, G., Andrini, E., Sisi, M., Rizzo, A., Parisi, C., Di Federico, A., ... & Ardizzoni, A. (2020). Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma. Critical Reviews in Oncology/Hematology, 156, Article 103119. https://doi.org/10.1016/j.critrevonc.2020.103119
8. Rajadurai, P., Cheah, P. L., How, S. H., Liam, C. K., Annuar, M. A. A., Omar, N., ... & MOS Molecular Testing Consensus Working Group. (2019). Molecular testing for advanced non-small cell lung cancer in Malaysia: Consensus statement from the College of Pathologists, Academy of Medicine Malaysia, the Malaysian Thoracic Society, and the Malaysian Oncological Society. Lung Cancer, 136, 65–73. https://doi.org/10.1016/j.lungcan.2019.08.012
9. Lin, J. J., Riely, G. J., & Shaw, A. T. (2017). Targeting ALK: Precision medicine takes on drug resistance. Cancer Discovery, 7(2), 137–155. https://doi.org/10.1158/2159-8290.CD-16-1123
10. Burrell, R. A., McGranahan, N., Bartek, J., & Swanton, C. (2013). The causes and consequences of genetic heterogeneity in cancer evolution. Nature, 501(7467), 338–345. https://doi.org/10.1038/nature12625
11. Esposito Abate, R., Frezzetti, D., Maiello, M. R., Gallo, M., Camerlingo, R., De Luca, A., ... & Normanno, N. (2020). Next generation sequencing-based profiling of cell free DNA in patients with advanced non-small cell lung cancer: Advantages and pitfalls. Cancers, 12(12), Article 3804. https://doi.org/10.3390/cancers12123804
12. Molina-Vila, M. A., Mayo-de-Las-Casas, C., Giménez-Capitán, A., Jordana-Ariza, N., Garzón, M., Balada, A., ... & Rosell, R. (2016). Liquid biopsy in non-small cell lung cancer. Frontiers in Medicine, 3, Article 69. https://doi.org/10.3389/fmed.2016.00069
13. Fernández-Lázaro, D., García Hernández, J. L., García, A. C., Córdova Martínez, A., Mielgo-Ayuso, J., & Cruz-Hernández, J. J. (2020). Liquid biopsy as novel tool in precision medicine: Origins, properties, identification and clinical perspective of cancer’s biomarkers. Diagnostics, 10(4), Article 215. https://doi.org/10.3390/diagnostics10040215
14. Zhang, Q., Fu, Q., Bai, X., & Liang, T. (2020). Molecular profiling-based precision medicine in cancer: A review of current evidence and challenges. Frontiers in Oncology, 10, Article 532403. https://doi.org/10.3389/fonc.2020.532403
15. Pisapia, P., Pepe, F., Baggi, A., Barberis, M., Galvano, A., Gristina, V., ... & Troncone, G. (2022). Next generation diagnostic algorithm in non-small cell lung cancer predictive molecular pathology: The KWAY Italian multicenter cost evaluation study. Critical Reviews in Oncology/Hematology, 169, Article 103525. https://doi.org/10.1016/j.critrevonc.2021.103525
16. Shu, Y., Wu, X., Tong, X., Wang, X., Chang, Z., Mao, Y., ... & Liu, L. (2017). Circulating tumor DNA mutation profiling by targeted next generation sequencing provides guidance for personalized treatments in multiple cancer types. Scientific Reports, 7(1), Article 583. https://doi.org/10.1038/s41598-017-00520-1
17. Guo, Q., Wang, J., Xiao, J., Wang, L., Hu, X., Yu, W., ... & Gu, Y. (2018). Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing. Molecular Cancer, 17(1), Article 131. https://doi.org/10.1186/s12943-018-0883-7
18. Veldore, V. H., Choughule, A., Routhu, T., Mandloi, N., Noronha, V., Joshi, A., ... & Dutt, A. (2018). Validation of liquid biopsy: Plasma cell-free DNA testing in clinical management of advanced non-small cell lung cancer. Lung Cancer: Targets and Therapy, 9, 1–11. https://doi.org/10.2147/LCTT.S149818
19. Kang, J. K., Heo, S., Kim, H. P., Song, S. H., Yun, H., Han, S. W., ... & Kim, T. Y. (2020). Liquid biopsy-based tumor profiling for metastatic colorectal cancer patients with ultra-deep targeted sequencing. PLoS ONE, 15(5), Article e0232754. https://doi.org/10.1371/journal.pone.0232754
20. Xu, B., Shan, G., Wu, Q., Li, W., Wang, H., Li, H., ... & Song, S. (2020). Concordance of genomic alterations between circulating tumor DNA and matched tumor tissue in Chinese patients with breast cancer. Journal of Oncology, 2020, Article 4259293. https://doi.org/10.1155/2020/4259293
21. Uchida, J., Kato, K., Kukita, Y., Kumagai, T., Nishino, K., Daga, H., ... & Imamura, F. (2015). Diagnostic accuracy of noninvasive genotyping of EGFR in lung cancer patients by deep sequencing of plasma cell-free DNA. Clinical Chemistry, 61(9), 1191–1196. https://doi.org/10.1373/clinchem.2015.241513
22. Chae, Y. K., Davis, A. A., Jain, S., Santa-Maria, C., Flaum, L., Beaubier, N., ... & Giles, F. J. (2017). Concordance of genomic alterations by next-generation sequencing in tumor tissue versus circulating tumor DNA in breast cancer. Molecular Cancer Therapeutics, 16(7), 1412–1420. https://doi.org/10.1158/1535-7163.MCT-17-0061
23. Hahn, A. W., Gill, D. M., Maughan, B., Agarwal, A., Arjyal, L., Gupta, S., ... & Pal, S. K. (2017). Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): Potential clinical implications. Oncotarget, 8(20), 33614–33620. https://doi.org/10.18632/oncotarget.16578
24. Cancer Genome Atlas Research Network. (2014). Comprehensive molecular profiling of lung adenocarcinoma. Nature, 511(7511), 543–550. https://doi.org/10.1038/nature13385
25. Sun, S., Du, W., Sun, Q., Zhao, X., Qin, B., Shi, D., ... & Meng, X. (2021). Driver gene alterations profiling of Chinese non-small cell lung cancer and the effects of co-occurring alterations on immunotherapy. Cancer Medicine, 10(20), 7360–7372. https://doi.org/10.1002/cam4.4227
26. Dang, A. H., Tran, V. U., Tran, T. T., Thi Pham, H. A., Le, D. T., Nguyen, L., ... & Phan, M. T. (2020). Actionable mutation profiles of non-small cell lung cancer patients from Vietnamese population. Scientific Reports, 10(1), Article 2707. https://doi.org/10.1038/s41598-020-59646-6
27. Chu, Q. S. (2020). Targeting non-small cell lung cancer: Driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion. Therapeutic Advances in Medical Oncology, 12, Article 1758835919895756. https://doi.org/10.1177/1758835919895756
28. Thorvaldsdóttir, H., Robinson, J. T., & Mesirov, J. P. (2013). Integrative Genomics Viewer (IGV): High-performance genomics data visualization and exploration. Briefings in Bioinformatics, 14(2), 178–192. https://doi.org/10.1093/bib/bbs017
29. Lanman, R. B., Mortimer, S. A., Zill, O. A., Sebisanovic, D., Lopez, R., Blau, S., ... & Talasaz, A. (2015). Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA. PLoS ONE, 10(10), Article e0140712. https://doi.org/10.1371/journal.pone.0140712
30. Wang, B., Wu, S., Huang, F., Shen, M., Jiang, H., Yu, Y., ... & Zhang, S. (2019). Analytical and clinical validation of a novel amplicon-based NGS assay for the evaluation of circulating tumor DNA in metastatic colorectal cancer patients. Clinical Chemistry and Laboratory Medicine, 57(10), 1501–1510. https://doi.org/10.1515/cclm-2018-1249
31. De Luca, G., Lastraioli, S., Conte, R., Mora, M., Genova, C., Rossi, G., ... & Coco, S. (2020). Performance of the Oncomine™ Lung cfDNA assay for liquid biopsy by NGS of NSCLC patients in routine laboratory practice. Applied Sciences, 10(8), Article 2895. https://doi.org/10.3390/app10082895
32. Peng, Q., Vijaya Satya, R., Lewis, M., Randad, P., & Wang, Y. (2015). Reducing amplification artifacts in high multiplex amplicon sequencing by using molecular barcodes. BMC Genomics, 16(1), Article 589. https://doi.org/10.1186/s12864-015-1806-y
33. Chung, J., Lee, K. W., Lee, C., Shin, SH., Kyung, S., Jeon, H. J., ... & Park, D. (2019). Performance evaluation of commercial library construction kits for PCR-based targeted sequencing using a unique molecular identifier. BMC Genomics, 20(1), Article 216. https://doi.org/10.1186/s12864-019-5567-3
34. Midha, A., Dearden, S., & McCormack, R. (2015). EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: A systematic review and global map by ethnicity (mutMapII). American Journal of Cancer Research, 5(9), 2892–2911.
35. Leal, L. F., de Paula, F. E., De Marchi, P., de Souza Viana, L., Pinto, G. D. J., Carlos, C. D., ... & Reis, R. M. (2019). Mutational profile of Brazilian lung adenocarcinoma unveils association of EGFR mutations with high Asian ancestry and independent prognostic role of KRAS mutations. Scientific Reports, 9(1), Article 3209. https://doi.org/10.1038/s41598-019-39953-x
36. Rajadurai, P., How, S. H., Liam, C. K., Sachithanandan, A., Soon, S. Y., & Tho, L. M. (2020). Lung cancer in Malaysia. Journal of Thoracic Oncology, 15(3), 317–323. https://doi.org/10.1016/j.jtho.2019.10.009
37. Okamoto, I., Morita, S., Tashiro, N., Imamura, F., Inoue, A., Seto, T., ... & Nakagawa, K. (2018). Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort. Lung Cancer, 117, 14–19. https://doi.org/10.1016/j.lungcan.2018.01.005
38. Kim, C., & Liu, S. V. (2019). First-line EGFR TKI therapy in non-small-cell lung cancer: Looking back before leaping forward. Annals of Oncology, 30(12), 1852–1855. https://doi.org/10.1093/annonc/mdz422
39. Ding, P. N., Becker, T., Bray, V., Chua, W., Ma, Y., Xu, B., ... & Lee, K. (2019). Plasma next generation sequencing and droplet digital PCR-based detection of epidermal growth factor receptor (EGFR) mutations in patients with advanced lung cancer treated with subsequent-line osimertinib. Thoracic Cancer, 10(10), 1879–1884. https://doi.org/10.1111/1759-7714.13158
40. Chan, D. L. H., Toh, G. L. X., & Goh, L. L. (2020). Clinical implementation of plasma EGFR T790M testing using droplet digital PCR in TKI-resistant NSCLC patients. Experimental and Molecular Pathology, 116, Article 104515. https://doi.org/10.1016/j.yexmp.2020.104515
41. Li, C., He, Q., Liang, H., Cheng, B., Li, J., Xiong, S., ... & Liang, W. (2020). Diagnostic accuracy of droplet digital PCR and amplification refractory mutation system PCR for detecting EGFR mutation in cell-free DNA of lung cancer: A meta-analysis. Frontiers in Oncology, 10, Article 290. https://doi.org/10.3389/fonc.2020.00290
42. Diehl, F., Schmidt, K., Choti, M. A., Romans, K., Goodman, S., Li, M., ... & Diaz, L. A., Jr. (2008). Circulating mutant DNA to assess tumor dynamics. Nature Medicine, 14(9), 985–990. https://doi.org/10.1038/nm.1789
43. Cescon, D. W., Bratman, S. V., Chan, S. M., & Siu, L. L. (2020). Circulating tumor DNA and liquid biopsy in oncology. Nature Cancer, 1(3), 276–290. https://doi.org/10.1038/s43018-020-0043-5
44. Eberhard, D. A., Johnson, B. E., Amler, L. C., Goddard, D. A., Heldens, S. L., Herbst, R. S., ... & Hillan, K. J. (2005). Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. Journal of Clinical Oncology, 23(25), 5900–5909. https://doi.org/10.1200/JCO.2005.11.008
45. Ohashi, K., Sequist, L. V., Arcila, M. E., Moran, T., Chmielecki, J., Lin, Y. L., ... & Pao, W. (2012). Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proceedings of the National Academy of Sciences, 109(31), E2127–E2133. https://doi.org/10.1073/pnas.1204014109
46. Takezawa, K., Pirazzoli, V., Arcila, M. E., Nebhan, C. A., Song, X., de Stanchina, E., ... & Pao, W. (2012). HER2 amplification: A potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFR T790M mutation. Cancer Discovery, 2(10), 922–933. https://doi.org/10.1158/2159-8290.CD-12-0108
47. Choughule, A., Sharma, R., Trivedi, V., Thavamani, A., Noronha, V., Joshi, A., ... & Dutt, A. (2014). Coexistence of KRAS mutation with mutant but not wild-type EGFR predicts response to tyrosine-kinase inhibitors in human lung cancer. British Journal of Cancer, 111(11), 2203–2204. https://doi.org/10.1038/bjc.2014.372
48. Li, S., Li, L., Zhu, Y., Huang, C., Qin, Y., Liu, H., ... & Zhang, S. (2014). Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: A comprehensive mutation profiling from 5,125 Chinese cohorts. British Journal of Cancer, 110(11), 2812–2820. https://doi.org/10.1038/bjc.2014.210
49. Del Re, M., Tiseo, M., Bordi, P., D’Incecco, A., Camerini, A., Petrini, I., ... & Danesi, R. (2017). Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: A study on circulating tumor DNA. Oncotarget, 8(8), 13611–13619. https://doi.org/10.18632/oncotarget.6955
50. Lee, T., Lee, B., Choi, Y. L., Han, J., Ahn, M. J., & Um, S. W. (2016). Non-small cell lung cancer with concomitant EGFR, KRAS, and ALK mutation: Clinicopathologic features of 12 cases. Journal of Pathology and Translational Medicine, 50(3), 197–203. https://doi.org/10.4132/jptm.2016.03.09
51. Carney, B. J., Rangachar, D., VanderLaan, P. A., Gowen, K., Schrock, A. B., Ali, S. M., ... & Costa, D. B. (2017). De novo ERBB2 amplification causing intrinsic resistance to erlotinib in EGFR-L858R mutated TKI-naïve lung adenocarcinoma. Lung Cancer, 114, 108–110. https://doi.org/10.1016/j.lungcan.2017.11.001
52. Rachiglio, A. M., Fenizia, F., Piccirillo, M. C., Galetta, D., Crinò, L., Vincenzi, B., ... & Normanno, N. (2019). The presence of concomitant mutations affects the activity of EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer (NSCLC) patients. Cancers, 11(3), Article 341. https://doi.org/10.3390/cancers11030341
53. Jia, Y., Ali, S. M., Saad, S., Chan, C. A., Miller, V. A., & Halmos, B. (2014). Successful treatment of a patient with Li-Fraumeni syndrome and metastatic lung adenocarcinoma harboring synchronous EGFR L858R and ERBB2 extracellular domain S310F mutations with the pan-HER inhibitor afatinib. Cancer Biology & Therapy, 15(8), 970–974. https://doi.org/10.4161/cbt.29135